Approval · Notice of Compliance 11048 · 2010
LISINOPRIL: Notice of Compliance 11048
Issued February 15, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11048
- Date
- February 15, 2010
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Angiotensin converting enzyme inhibitor
- Canadian reference product
- ZESTRIL (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LISINOPRIL | 02343576 | Cancelled Pre Market |
| LISINOPRIL | 02343584 | Cancelled Pre Market |
| LISINOPRIL | 02343592 | Cancelled Pre Market |
Medicinal ingredients
- LISINOPRIL 5 MG per TAB
- LISINOPRIL 10 MG per TAB
- LISINOPRIL 20 MG per TAB